S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
CLYM · Climb Bio, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
$10.86
+0.04
(+0.37%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$10.86
$10.78
$11.25
52-WEEK RANGE
$10.86
$1.64
$18.33
What's happening
- CLYM is up 0.37% today, trading at $10.86. — Live quote
- Volume today (54,026) is well below its 3-month average of 1,383,110. (Finnhub fundamentals)
- Reports earnings on 2026-11-11, 20 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.18 actual vs. $-0.22 estimated (+17.4%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 10
Buy 10
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (21 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
CLYM
+170.00%
vs S&P 500
+157.22%
1-YEAR RETURN
CLYM
+365.52%
vs S&P 500
+350.96%
6-MONTH RETURN
CLYM
+22.45%
3-MONTH RETURN
CLYM
-17.56%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.18
Est. $-0.22
BEAT +17.4%
2026-04-26 (Q1 2026)
$-0.20
Est. $-0.27
BEAT +26.5%
2026-01-26 (Q4 2025)
$-0.26
Est. $-0.20
MISS -29.4%
2025-10-26 (Q3 2025)
$-0.19
Est. $-0.15
MISS -27.0%
Valuation Measures & Ratios
Enterprise Value4$576.2M
Forward P/E5—
PEG Ratio6-0.61
Price / Sales (TTM1)—
Price / Book73.12
EV4 / Revenue—
EV4 / EBITDA—
Profit Margin—
Operating Margin—
Return on Equity (ROE8)-31.79%
Return on Assets (ROA9)-30.79%
Avg Volume (3M)1,383,110
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $979.7M | $470.0M | $136.3M | $82.3M | $82.5M |
| P/E | -20.09 | -8.38 | -2.66 | -0.88 | -0.96 |
| Price/Book | 4.09 | 3.17 | 0.77 | 0.44 | 0.43 |
| EV/EBITDA | -16.71 | -7.25 | -1.83 | — | — |
| ROE | -20.36% | -37.85% | -28.94% | -50.19% | -44.61% |
| ROA | -19.80% | -36.79% | -28.10% | -48.46% | -42.97% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short9,718,558
Change from Prior Settlement+14.22%
% of Float—
Days to Cover (Short Ratio)5.64
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Trailing 52-week price return is +365.5%. Finnhub market metrics ↗
Potential concerns
- Latest SEC filing is Form 4, filed 2026-09-30; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on CLYM
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Operating income | -$15.4M | -$15.2M | -$14.9M | -$10.7M | -$23.0M | -$11.7M | -$56.4M | -$3.0M |
| Net income | -$13.5M | -$13.7M | -$12.9M | -$8.7M | -$20.8M | -$8.9M | -$54.9M | -$1.7M |
| EPS (diluted) | $-0.18 | $-0.20 | $-0.19 | $-0.13 | $-0.31 | $-0.13 | $-1.81 | $-0.06 |
| EPS (basic) | $-0.18 | $-0.20 | $-0.19 | $-0.13 | $-0.31 | $-0.13 | $-1.81 | $-0.06 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $246.3M | $152.4M | $167.7M | $182.3M | $192.4M | $200.7M | $217.2M | $222.2M |
| Total liabilities | $6.7M | $4.3M | $7.3M | $5.3M | $6.6M | $7.4M | $5.3M | $3.4M |
| Stockholders' equity | $239.5M | $148.1M | $160.5M | $177.0M | $185.8M | $193.4M | $211.9M | $218.8M |
| Total current assets | $186.6M | $113.4M | $105.8M | $91.0M | $87.4M | $100.3M | $154.9M | $197.6M |
| Total current liabilities | $5.9M | $4.1M | $7.0M | $4.9M | $6.2M | $7.0M | $4.9M | $3.4M |
| Cash & equivalents | $44.1M | $8.4M | $35.7M | $25.8M | $22.7M | $29.0M | $87.2M | $146.2M |
| Marketable securities (current) | $139.0M | $101.2M | $65.4M | $61.1M | $62.0M | $69.0M | $63.7M | $47.2M |
| Marketable securities (non-current) | $56.1M | $36.7M | $59.6M | $88.9M | $102.7M | $99.8M | $61.6M | $24.6M |
| Property, plant & equipment | $695.0K | $250.0K | $288.0K | $318.0K | $314.0K | — | $199.0K | — |
| Other non-current assets | $1.6M | $1.5M | $1.5M | $1.5M | $1.4M | $226.0K | $16.0K | $0 |
| Accounts payable | $1.1M | $860.0K | $2.3M | $477.0K | $946.0K | $777.0K | $705.0K | $291.0K |
| Accrued liabilities | — | — | — | — | — | $6.1M | $4.1M | $3.0M |
| Other current liabilities | — | — | — | — | — | — | $31.0K | $22.0K |
| Other non-current liabilities | — | — | — | — | — | — | $0 | $0 |
| Common stock & paid-in capital | $6.0K | $5.0K | $5.0K | $7.0K | $7.0K | $7.0K | $7.0K | $7.0K |
| Retained earnings | -$316.9M | -$303.4M | -$289.7M | -$272.2M | -$259.3M | -$250.7M | -$229.9M | -$221.5M |
| Accumulated other comprehensive income (loss) | -$67.0K | $157.0K | $435.0K | $469.0K | $318.0K | $286.0K | $23.0K | $201.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$10.5M | -$14.4M | -$15.6M | -$12.1M | -$11.1M | -$15.4M | -$5.5M | -$7.6M |
| Investing cash flow | -$57.3M | -$13.0M | $25.5M | $15.3M | $4.8M | -$42.8M | -$53.4M | -$71.8M |
| Financing cash flow | $103.7M | $5.0K | -$21.0K | $0 | $0 | $0 | $41.0K | $2.3M |
| Free cash flow | -$10.8M | — | -$15.6M | -$12.2M | -$11.2M | — | -$5.5M | -$7.6M |
| Capital expenditures | $260.0K | — | $0 | $109.0K | $77.0K | — | $0 | $0 |
| Depreciation & amortization | $33.0K | $38.0K | $30.0K | $29.0K | $38.0K | $0 | $0 | $0 |
| Share-based compensation | $1.5M | $1.6M | $1.0M | $4.0M | $1.0M | $2.0M | $1.7M | $2.9M |
| Change in accounts payable | $200.0K | -$1.4M | $1.8M | -$393.0K | $93.0K | $72.0K | $414.0K | -$217.0K |
| Purchases of investments | $82.6M | $44.9M | $5.0M | $23.7M | $20.6M | $58.8M | $60.4M | $71.8M |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating income | -$67.9M | -$82.0M | -$40.3M | -$45.1M | -$35.7M |
| Net income | -$59.9M | -$73.9M | -$35.1M | -$45.2M | -$47.5M |
| EPS (diluted) | $-0.88 | $-1.53 | $-1.30 | $-1.72 | $-4.24 |
| EPS (basic) | $-0.88 | $-1.53 | $-1.30 | $-1.72 | $-4.24 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $167.7M | $217.2M | $110.5M | $135.0M | $173.2M |
| Total liabilities | $7.3M | $5.3M | $2.9M | $6.3M | $6.0M |
| Stockholders' equity | $160.5M | $211.9M | $107.6M | $128.7M | $167.2M |
| Total current assets | $105.8M | $154.9M | $110.3M | $134.4M | $148.3M |
| Total current liabilities | $7.0M | $4.9M | $2.8M | $6.1M | $6.0M |
| Cash & equivalents | $35.7M | $87.2M | $93.1M | $43.6M | $46.9M |
| Marketable securities (current) | $65.4M | $63.7M | $13.7M | $80.0M | $89.6M |
| Marketable securities (non-current) | $59.6M | $61.6M | $0 | $0 | $24.9M |
| Property, plant & equipment | $288.0K | $199.0K | — | — | — |
| Other non-current assets | $1.5M | $16.0K | $15.0K | $128.0K | $70.0K |
| Accounts payable | $2.3M | $705.0K | $66.0K | $750.0K | $1.4M |
| Accrued liabilities | — | $4.1M | $2.4M | $5.0M | $4.6M |
| Other current liabilities | — | $31.0K | $138.0K | $0 | — |
| Other non-current liabilities | — | $0 | $22.0K | $0 | $7.0K |
| Common stock & paid-in capital | $5.0K | $7.0K | $3.0K | $3.0K | $3.0K |
| Retained earnings | -$289.7M | -$229.9M | -$156.0M | -$120.9M | -$75.6M |
| Accumulated other comprehensive income (loss) | $435.0K | $23.0K | -$2.0K | -$358.0K | -$123.0K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$54.4M | -$15.6M | -$20.6M | -$37.4M | -$36.1M |
| Investing cash flow | $2.8M | -$121.1M | $69.0M | $34.4M | -$115.0M |
| Financing cash flow | -$21.0K | $130.7M | $841.0K | $0 | $177.2M |
| Free cash flow | -$54.5M | -$15.6M | — | — | — |
| Capital expenditures | $186.0K | $0 | — | — | — |
| Depreciation & amortization | $97.0K | $0 | — | — | — |
| Share-based compensation | $8.1M | $5.6M | $12.8M | $7.0M | $3.7M |
| Change in accounts payable | $1.6M | -$963.0K | -$686.0K | -$653.0K | $318.0K |
| Purchases of investments | $108.1M | $132.2M | $58.4M | $88.0M | $115.0M |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding CLYM as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-06-27 to 2026-09-28
Recent transactions
- Insiders have net sold 130,902 shares over the last 182 days, across 0 purchases and 2 sales.
- Most recent: RA CAPITAL MANAGEMENT, L.P. (Reporting person) — Option exercise of 10,000 shares on 2026-09-28.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)130,902 sh(2 txns)
Net Shares-130,902
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | Reporting person | Option exercise | 2026-09-28 | 10,000 |
| Thomas Stephen Basil | Reporting person | Open market sale | 2026-09-15 | 100,000 |
| Brennan Aoife | President and CEO | Open market sale | 2026-06-29 | 30,902 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-28 | RA CAPITAL MANAGEMENT, L.P. | Reporting person | Option exercise | 10,000 | $3.46 |
| 2026-09-28 | RA CAPITAL MANAGEMENT, L.P. | Reporting person | Option exercise | 10,000 | $3.00 |
| 2026-09-28 | RA CAPITAL MANAGEMENT, L.P. | Reporting person | Option exercise | 10,000 | $7.89 |
| 2026-09-28 | RA CAPITAL MANAGEMENT, L.P. | Reporting person | Option exercise | 40,000 | $1.29 |
| 2026-09-15 | Thomas Stephen Basil | Reporting person | Open market sale | 100,000 | $13.67 |
| 2026-06-29 | Brennan Aoife | President and CEO | Open market sale | 30,902 | $13.17 |
| 2026-06-27 | Brennan Aoife | President and CEO | Option exercise | 68,750 | — |
| 2026-02-26 | Thomas Stephen Basil | Reporting person | Open market sale | 16,313 | $7.01 |
| 2026-02-25 | Thomas Stephen Basil | Reporting person | Open market sale | 33,687 | $7.00 |
| 2026-02-13 | Thomas Stephen Basil | Reporting person | Open market sale | 10,000 | $5.81 |
| 2026-02-12 | Thomas Stephen Basil | Reporting person | Open market sale | 90,000 | $5.23 |
| 2026-01-05 | RA CAPITAL MANAGEMENT, L.P. | Reporting person | Open market purchase | 7,111 | $3.50 |
| 2025-12-12 | RA CAPITAL MANAGEMENT, L.P. | Reporting person | Open market purchase | 101,462 | $2.86 |
| 2025-12-11 | RA CAPITAL MANAGEMENT, L.P. | Reporting person | Disposition to issuer | 20,440,000 | $0.00 |
| 2025-12-11 | RA CAPITAL MANAGEMENT, L.P. | Reporting person | Open market purchase | 213,099 | $2.18 |
| 2025-08-07 | Thomas Stephen Basil | Reporting person | Grant / award | 100,375 | $0.00 |
| 2025-06-30 | Brennan Aoife | President and CEO | Open market sale | 20,618 | $1.22 |
| 2025-06-27 | Brennan Aoife | President and CEO | Option exercise | 68,750 | — |
| 2025-06-27 | Thomas Stephen Basil | Reporting person | Option exercise | 25,094 | — |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-21 23:17 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-09-30 | 4 | 2026-09-28 | View on SEC.gov → |
| 2026-09-17 | 4 | 2026-09-15 | View on SEC.gov → |
| 2026-09-03 | 8-K | 2026-09-03 | View on SEC.gov → |
| 2026-08-14 | 8-K | 2026-08-13 | View on SEC.gov → |
| 2026-08-06 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-06 | 8-K | 2026-08-06 | View on SEC.gov → |
| 2026-07-01 | 4 | 2026-06-29 | View on SEC.gov → |
| 2026-07-01 | 4 | 2026-06-29 | View on SEC.gov → |
| 2026-07-01 | 8-K | 2026-06-29 | View on SEC.gov → |
| 2026-06-30 | 4 | 2026-06-27 | View on SEC.gov → |
| 2026-06-12 | 8-K | 2026-06-11 | View on SEC.gov → |
| 2026-06-11 | 8-K | 2026-06-11 | View on SEC.gov → |
Recent news
Headlines about CLYM (Climb Bio, Inc.). Links open the publisher — we don’t host full articles.
-
CLYM Oct 2026 30.000 call (CLYM261016C00030000) Interactive Stock Chart
Yahoo! Finance Canada · 2026-10-21 -
Climb Bio, Inc. (CLYM) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-20 -
Climb Bio stock initiated at buy by Deutsche Bank on autoimmune pipeline
Investing.com Nigeria · 2026-10-20 -
Why is Climb Bio stock surging today? By Investing.com
Investing.com South Africa · 2026-10-20 -
Deutsche Bank starts Climb Bio at Buy, citing compelling autoimmune pipeline
Yahoo · 2026-10-20 -
Deutsche Bank Initiates Coverage On Climb Bio with Buy Rating, Announces Price Target of $28
Benzinga · 2026-10-20 -
Are Medical Stocks Lagging Climb Bio, Inc. (CLYM) This Year?
Yahoo · 2026-10-20 -
Understanding Momentum Shifts in (CLYM)
Stock Traders Daily · 2026-10-18
No headlines in this category right now — try “All”.